Cargando…

Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer

PURPOSE: To assess the therapeutic response for metastatic breast cancer with (18)F-FDG position emission tomography (PET), this retrospective study aims to compare the performance of six different metabolic metrics with PERCIST, PERCIST with optimal thresholds, and an image-based parametric approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulon, Dorothée, Necib, Hatem, Henaff, Brice, Rousseau, Caroline, Carlier, Thomas, Kraeber-Bodere, Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861036/
https://www.ncbi.nlm.nih.gov/pubmed/27243012
http://dx.doi.org/10.3389/fmed.2016.00019
_version_ 1782431168093749248
author Goulon, Dorothée
Necib, Hatem
Henaff, Brice
Rousseau, Caroline
Carlier, Thomas
Kraeber-Bodere, Françoise
author_facet Goulon, Dorothée
Necib, Hatem
Henaff, Brice
Rousseau, Caroline
Carlier, Thomas
Kraeber-Bodere, Françoise
author_sort Goulon, Dorothée
collection PubMed
description PURPOSE: To assess the therapeutic response for metastatic breast cancer with (18)F-FDG position emission tomography (PET), this retrospective study aims to compare the performance of six different metabolic metrics with PERCIST, PERCIST with optimal thresholds, and an image-based parametric approach. METHODS: Thirty-six metastatic breast cancer patients underwent 128 PET scans and 123 lesions were identified. In a per-lesion and per-patient analysis, the performance of six metrics: maximum standardized uptake value (SUVmax), SUVpeak, standardized added metabolic activity (SAM), SUVmean, metabolic volume (MV), total lesion glycolysis (TLG), and a parametric approach (SULTAN) were determined and compared to the gold standard (defined by clinical assessment and biological and conventional imaging according RECIST 1.1). The evaluation was performed using PERCIST thresholds (for per-patient analysis only) and optimal thresholds (determined by the Youden criterion from the receiver operating characteristic curves). RESULTS: In the per-lesion analysis, 210 pairs of lesion evolutions were studied. Using the optimal thresholds, SUVmax, SUVpeak, SUVmean, SAM, and TLG were significantly correlated with the gold standard. SUVmax, SUVpeak, and SUVmean reached the best sensitivity (91, 88, and 83%, respectively), specificity (93, 95, and 97%, respectively), and negative predictive value (NPV, 90, 88, and 83%, respectively). For the per-­patient analysis, 79 pairs of PET were studied. The optimal thresholds compared to the PERCIST threshold did not improve performance for SUVmax, SUVpeak, and SUVmean. Only SUVmax, SUVpeak, SUVmean, and TLG were correlated with the gold standard. SULTAN also performed equally: 83% sensitivity, 88% specificity, and NPV 86%. CONCLUSION: This study showed that SUVmax and SUVpeak were the best parameters for PET evaluation of metastatic breast cancer lesions. Parametric imaging is helpful in evaluating serial studies.
format Online
Article
Text
id pubmed-4861036
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-48610362016-05-30 Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer Goulon, Dorothée Necib, Hatem Henaff, Brice Rousseau, Caroline Carlier, Thomas Kraeber-Bodere, Françoise Front Med (Lausanne) Medicine PURPOSE: To assess the therapeutic response for metastatic breast cancer with (18)F-FDG position emission tomography (PET), this retrospective study aims to compare the performance of six different metabolic metrics with PERCIST, PERCIST with optimal thresholds, and an image-based parametric approach. METHODS: Thirty-six metastatic breast cancer patients underwent 128 PET scans and 123 lesions were identified. In a per-lesion and per-patient analysis, the performance of six metrics: maximum standardized uptake value (SUVmax), SUVpeak, standardized added metabolic activity (SAM), SUVmean, metabolic volume (MV), total lesion glycolysis (TLG), and a parametric approach (SULTAN) were determined and compared to the gold standard (defined by clinical assessment and biological and conventional imaging according RECIST 1.1). The evaluation was performed using PERCIST thresholds (for per-patient analysis only) and optimal thresholds (determined by the Youden criterion from the receiver operating characteristic curves). RESULTS: In the per-lesion analysis, 210 pairs of lesion evolutions were studied. Using the optimal thresholds, SUVmax, SUVpeak, SUVmean, SAM, and TLG were significantly correlated with the gold standard. SUVmax, SUVpeak, and SUVmean reached the best sensitivity (91, 88, and 83%, respectively), specificity (93, 95, and 97%, respectively), and negative predictive value (NPV, 90, 88, and 83%, respectively). For the per-­patient analysis, 79 pairs of PET were studied. The optimal thresholds compared to the PERCIST threshold did not improve performance for SUVmax, SUVpeak, and SUVmean. Only SUVmax, SUVpeak, SUVmean, and TLG were correlated with the gold standard. SULTAN also performed equally: 83% sensitivity, 88% specificity, and NPV 86%. CONCLUSION: This study showed that SUVmax and SUVpeak were the best parameters for PET evaluation of metastatic breast cancer lesions. Parametric imaging is helpful in evaluating serial studies. Frontiers Media S.A. 2016-05-09 /pmc/articles/PMC4861036/ /pubmed/27243012 http://dx.doi.org/10.3389/fmed.2016.00019 Text en Copyright © 2016 Goulon, Necib, Henaff, Rousseau, Carlier and Kraeber-Bodere. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Goulon, Dorothée
Necib, Hatem
Henaff, Brice
Rousseau, Caroline
Carlier, Thomas
Kraeber-Bodere, Françoise
Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
title Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
title_full Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
title_fullStr Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
title_full_unstemmed Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
title_short Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer
title_sort quantitative evaluation of therapeutic response by fdg-pet–ct in metastatic breast cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861036/
https://www.ncbi.nlm.nih.gov/pubmed/27243012
http://dx.doi.org/10.3389/fmed.2016.00019
work_keys_str_mv AT goulondorothee quantitativeevaluationoftherapeuticresponsebyfdgpetctinmetastaticbreastcancer
AT necibhatem quantitativeevaluationoftherapeuticresponsebyfdgpetctinmetastaticbreastcancer
AT henaffbrice quantitativeevaluationoftherapeuticresponsebyfdgpetctinmetastaticbreastcancer
AT rousseaucaroline quantitativeevaluationoftherapeuticresponsebyfdgpetctinmetastaticbreastcancer
AT carlierthomas quantitativeevaluationoftherapeuticresponsebyfdgpetctinmetastaticbreastcancer
AT kraeberboderefrancoise quantitativeevaluationoftherapeuticresponsebyfdgpetctinmetastaticbreastcancer